文献速递耳科与耳神经

干细胞治疗听力损失的研究进展

Advances in Stem Cell Therapy for Hearing Loss.
PubMed 文献 · Ear Hear · 2026-10-13

感音神经性听力损失由耳蜗毛细胞、耳蜗神经或中枢听觉通路损伤引起,现有助听器和人工耳蜗疗效有限,且尚无FDA批准的细胞、分子或药理疗法。干细胞治疗通过向耳蜗移植外源干细胞成为新兴方向,二维培养助力理解多能干细胞在内耳神经上皮的分化,三维内耳类器官则更接近体内结构,未来方向包括与基因治疗整合及高通量药物筛选平台。

要点

  • 感音神经性听力损失累及毛细胞、螺旋神经节神经元和螺旋韧带纤维细胞,这些结构再生能力有限。
  • 三维内耳类器官分化方案较二维培养更接近体内结构,是干细胞治疗的重要进展。
  • 未来方向包括干细胞治疗与基因治疗整合及开发新型高通量药物筛选平台。

核心结论

  • 干细胞治疗是治疗感音神经性听力损失的新兴有前景的方法,通过向耳蜗移植外源干细胞实现。
  • 三维内耳类器官分化方案更接近体内结构,是干细胞治疗发展的有希望的一步。

研究设计与样本

  • 综述类文章,未报告系统检索范围。

主要发现

  • 感音神经性听力损失由耳蜗毛细胞、耳蜗神经或中枢听觉通路损伤引起,占听力损失大多数病例。
  • 现有助听器和人工耳蜗在噪声环境中疗效有限、听力结果可变且频率分辨有限。
  • 目前尚无FDA批准的细胞、分子或药理疗法可用于听力损失。
  • 二维培养系统有助于理解多能干细胞在内耳神经上皮的分化,但无法模拟组织特异性结构和细胞相互作用。
  • 三维内耳类器官分化方案更接近体内结构,针对耳蜗中再生能力有限或无再生能力的结构。

临床怎么用

  • 干细胞治疗目前仍处于研究阶段,尚未有FDA批准的细胞、分子或药理疗法可供临床使用。
  • 三维内耳类器官可作为研究干细胞模拟或恢复内耳功能的平台。

局限性

  • 二维培养系统无法模拟组织特异性结构和特定细胞相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hearing loss is the most common sensory disorder, causing substantial impacts on language development, literacy, mood, and cognition. Sensorineural hearing loss, caused by injury to the cochlear hair cells, cochlear nerve, or central auditory pathways, accounts for most cases of hearing loss. Existing therapies for sensorineural hearing loss include hearing aids and cochlear implants; however, these modalities have limited efficacy in noisy environments, variable hearing outcomes, and limited frequency discrimination. There are currently no Food and Drug Administration-approved cellular, molecular, or pharmacological therapies available. Stem cell therapy is an emerging and promising approach to treating sensorineural hearing loss through transplanting exogenous stem cells into the cochlea. Stem cell-based inner ear systems have been crucial to studying how stem cells can mimic or restore the function of the inner ear. The two-dimensional culture system has been instrumental in understanding pluripotent stem cell differentiation in the inner ear neuroepithelium. However, they are unable to mimic tissue-specific architecture and specific cellular interactions. Researchers subsequently moved to develop differentiation protocols in three-dimensional inner ear organoids, which more closely resemble in vivo structures. Such approaches are a promising step forward in the development of stem cell therapies focusing on structures in the cochlea that have limited to no ability to regenerate, including hair cells, spiral ganglion neurons, and spiral ligament fibrocytes. Future directions of this field include integrating stem cell therapy with gene therapy approaches and developing novel high-throughput drug screening platforms.

来源:Ear Hear,查看原文。版权归原作者所有。

引用

  1. Krishnan PS, Jung D, Morris JA, et al. Advances in Stem Cell Therapy for Hearing Loss. Ear Hear. 2026. PMID: 42868225. doi:10.1097/AUD.0000000000001813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。